Literature DB >> 18359864

Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM.

Rose Du1, Claudia Petritsch, Kan Lu, Patty Liu, Anna Haller, Ruth Ganss, Hanqiu Song, Scott Vandenberg, Gabriele Bergers.   

Abstract

Glioblastoma multiforme (GBM) is one the most aggressive brain tumors due to the fast and invasive growth that is partly supported by the presence of extensive neovascularization. The matrix metalloproteinase MMP-2 has been associated with invasive and angiogenic properties in gliomas and is a marker of poor prognosis. Since MMP-2 is expressed in both tumor cells and endothelial cells in GBM, we generated genetically engineered MMP-2 knockout (MMP-2ko) GBM to examine the importance of the spatial expression of MMP-2 in tumor and/or normal host-derived cells. MMP-2-dependent effects appeared to be dose-dependent irrespective of its expression pattern. GBM completely devoid of MMP-2 exhibited markedly increased vascular density associated with vascular endothelial growth factor receptor 2 (VEGFR2) activation and enhanced vascular branching and sprouting. Surprisingly, despite the high vascular density, tumor cells were more prone to apoptosis, which led to prolonged survival of tumor-bearing mice, suggesting that the increased vascularity is not functional. Congruently, tumor vessels were poorly perfused, exhibited lower levels of VEGFR2, and did not undergo proper maturation because pericytes of MMP-2ko tumors were not activated and were less abundant. As a result of impaired and dysfunctional angiogenesis, MMP-2ko GBM became more invasive, predominantly by migrating along blood vessels into the brain parenchyma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18359864      PMCID: PMC2563048          DOI: 10.1215/15228517-2008-001

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  28 in total

Review 1.  Regulation of matrix biology by matrix metalloproteinases.

Authors:  Joni D Mott; Zena Werb
Journal:  Curr Opin Cell Biol       Date:  2004-10       Impact factor: 8.382

2.  Vascular endothelial growth factor as a marker of tumor endothelium.

Authors:  R A Brekken; X Huang; S W King; P E Thorpe
Journal:  Cancer Res       Date:  1998-05-01       Impact factor: 12.701

3.  Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma.

Authors:  P D Brown; R E Bloxidge; N S Stuart; K C Gatter; J Carmichael
Journal:  J Natl Cancer Inst       Date:  1993-04-07       Impact factor: 13.506

4.  Reduced angiogenesis and tumor progression in gelatinase A-deficient mice.

Authors:  T Itoh; M Tanioka; H Yoshida; T Yoshioka; H Nishimoto; S Itohara
Journal:  Cancer Res       Date:  1998-03-01       Impact factor: 12.701

5.  The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors.

Authors:  P Naik; J Karrim; D Hanahan
Journal:  Genes Dev       Date:  1996-09-01       Impact factor: 11.361

6.  Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value.

Authors:  A Väisänen; H Tuominen; M Kallioinen; T Turpeenniemi-Hujanen
Journal:  J Pathol       Date:  1996-11       Impact factor: 7.996

7.  Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas.

Authors:  V Thorns; G F Walter; C Thorns
Journal:  Anticancer Res       Date:  2003 Sep-Oct       Impact factor: 2.480

8.  Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies.

Authors:  T M Sioussat; H F Dvorak; T A Brock; D R Senger
Journal:  Arch Biochem Biophys       Date:  1993-02-15       Impact factor: 4.013

9.  Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization.

Authors:  Mario Berger; Gabriele Bergers; Bernd Arnold; Günter J Hämmerling; Ruth Ganss
Journal:  Blood       Date:  2004-09-30       Impact factor: 22.113

10.  The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades.

Authors:  Maode Wang; Tuo Wang; Shuoxun Liu; Daizo Yoshida; Akira Teramoto
Journal:  Brain Tumor Pathol       Date:  2003       Impact factor: 3.298

View more
  57 in total

1.  CXCR2-Dependent Endothelial Progenitor Cell Mobilization in Pancreatic Cancer Growth.

Authors:  Aihua Li; Xiao J Cheng; Aune Moro; Rakesh K Singh; Oscar Joe Hines; Guido Eibl
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

2.  Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.

Authors:  Shih-Chi Su; Xiaoxiao Hu; Patrick A Kenney; Megan M Merrill; Kara N Babaian; Xiu-Ying Zhang; Tapati Maity; Shun-Fa Yang; Xin Lin; Christopher G Wood
Journal:  Clin Cancer Res       Date:  2013-10-11       Impact factor: 12.531

3.  Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression.

Authors:  Laurie E Littlepage; Mark D Sternlicht; Nathalie Rougier; Joanna Phillips; Eugenio Gallo; Ying Yu; Kurt Williams; Audrey Brenot; Jeffrey I Gordon; Zena Werb
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

Review 4.  Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Matrix Biol       Date:  2015-04-22       Impact factor: 11.583

5.  MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma.

Authors:  Emeline Tabouret; Françoise Boudouresque; Patrizia Farina; Maryline Barrié; Céline Bequet; Marc Sanson; Olivier Chinot
Journal:  Neuro Oncol       Date:  2015-08       Impact factor: 12.300

6.  CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A2B Adenosine Receptor Signaling.

Authors:  Angela Yan; Michelle L Joachims; Linda F Thompson; Andrew D Miller; Peter D Canoll; Margaret S Bynoe
Journal:  J Neurosci       Date:  2019-03-29       Impact factor: 6.167

Review 7.  Tumor microenvironment and progression.

Authors:  Harold F Dvorak; Valerie M Weaver; Thea D Tlsty; Gabriele Bergers
Journal:  J Surg Oncol       Date:  2011-05-01       Impact factor: 3.454

8.  Matrix metalloproteinase 2 (MMP-2) degrades soluble vasculotropic amyloid-beta E22Q and L34V mutants, delaying their toxicity for human brain microvascular endothelial cells.

Authors:  Mar Hernandez-Guillamon; Stephanie Mawhirt; Silvia Fossati; Steven Blais; Mireia Pares; Anna Penalba; Merce Boada; Pierre-Olivier Couraud; Thomas A Neubert; Joan Montaner; Jorge Ghiso; Agueda Rostagno
Journal:  J Biol Chem       Date:  2010-06-24       Impact factor: 5.157

9.  Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.

Authors:  Emeline Tabouret; Françoise Boudouresque; Maryline Barrie; Mona Matta; Celine Boucard; Anderson Loundou; Antoine Carpentier; Marc Sanson; Philippe Metellus; Dominique Figarella-Branger; L'houcine Ouafik; Olivier Chinot
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

10.  Deficiency in matrix metalloproteinase-2 results in long-term vascular instability and regression in the injured mouse spinal cord.

Authors:  Alpa Trivedi; Haoqian Zhang; Adanma Ekeledo; Sangmi Lee; Zena Werb; Giles W Plant; Linda J Noble-Haeusslein
Journal:  Exp Neurol       Date:  2016-07-25       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.